Search results
Takashi YOKOI, Associate Professor | Cited by 4,000 | of Hyogo College of Medicine, Nishinomiya-hama | Read 76 publications | Contact Takashi YOKOI
The results of this retrospective study show that the pemetrexed regimen, but not the paclitaxel regimen, was related to poor clinical outcomes in elderly patients with NSCLC.
- Kenji Morimoto, Tadaaki Yamada, Takashi Yokoi, Takashi Kijima, Yasuhiro Goto, Akira Nakao, Makoto Hi...
- 2021
Nov 16, 2017 · Approximately one third of patients with non–small-cell lung cancer (NSCLC) have stage III, locally advanced disease at diagnosis. 1 The standard of care for patients with a good performance status...
- Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yo...
- 2017
Summary. Background In the ongoing, phase 3 PACIFIC trial, durvalumab improved the primary endpoints of progression-free survival and overall survival compared with that for placebo, with similar safety, in patients with unresectable, stage III non-small-cell lung cancer.
Nov 16, 2017 · This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.
- Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yo...
- 2017
Takashi Yokoi's 32 research works with 199 citations and 2,908 reads, including: Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to...
Apr 4, 2022 · Updated PFS was consistent with the primary analysis, with a 45% reduction in the risk of disease progression or death with durvalumab versus placebo (stratified HR, 0.55; 95% CI, 0.45 to 0.68; Fig. . 2 B). 1 Median PFS was 16.9 months with durvalumab versus 5.6 months with placebo.
